SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,832.95 |
Enterprise Value ($M) | 1,763.62 |
Book Value ($M) | 1,035.73 |
Book Value / Share | 18.56 |
Price / Book | 1.77 |
NCAV ($M) | 353.73 |
NCAV / Share | 6.34 |
Price / NCAV | 5.18 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.07 |
Return on Assets (ROA) | 0.06 |
Return on Equity (ROE) | 0.08 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.16 |
Current Ratio | 2.35 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 686.07 |
Assets | 1,368.07 |
Liabilities | 332.34 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 661.82 |
Operating Income | 61.36 |
Net Income | 73.86 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 171.95 |
Cash from Investing | -189.87 |
Cash from Financing | 12.19 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Armistice Capital, Llc | 8.76 | -5.10 | |
13G/A | Macquarie Group Ltd | 4.78 | -3.87 | |
13G | Dimensional Fund Advisors Lp | 5.20 | ||
13G/A | Vanguard Group Inc | 11.38 | 7.34 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
335,372 | 1,169,720 | 28.67 | |
204,643 | 583,599 | 35.07 | |
185,420 | 470,149 | 39.44 | |
115,848 | 376,632 | 30.76 | |
(click for more detail) |
Similar Companies | |
---|---|
SMMT – Summit Therapeutics Inc. | SPRY – ARS Pharmaceuticals, Inc. |
STRO – Sutro Biopharma, Inc. | TARA – Protara Therapeutics, Inc. |
TBPH – Theravance Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io